20.02

5.67% +1.1165

Silk Road Medical Inc (SILK)

Overview News Price History Option Chain Financials Why SILK Down? Discussions Forecast

Silk Road Medical Inc stock is currently priced at $20.02, with a 24-hour trading volume of 316.17K. It has seen a +5.67% increased in the last 24 hours and a +12.52% rose in the past month. The chart indicates a potential bullish trend, as the stock is above the $19.49 pivot point. If it approaches the $20.14 resistance level, significant changes may occur.

Previous Close:

$18.90

Open:

$19.46

24h Volume:

316.17K

Market Cap:

$790.81M

Revenue:

$177.13M

Net Income/Loss:

$-55.74M

P/E Ratio:

-14.20

EPS:

-1.41

Net Cash Flow:

$-33.52M

1W Performance:

+12.20%

1M Performance:

+12.52%

6M Performance:

+127.99%

1Y Performance:

-52.23%

1D Range:

$19.35

$20.29

52W Range:

$6.08

$43.52

Silk Road Medical Inc Stock (SILK) Company Profile

Name

Silk Road Medical Inc

Sector

Healthcare (1223)

Industry

Medical Devices (156)

Phone

408-720-9002

Address

1213 Innsbruck Drive, Sunnyvale, CA

Employee

176

Twitter

@SilkRoadMed

Next Earnings Date

2024-05-14

Latest SEC Filings

SILK's Discussions on Twitter

Silk Road Medical Inc Stock (SILK) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-21-23	Downgrade	Argus	Buy → Hold
Sep-06-23	Initiated	Oppenheimer	Outperform
Jul-12-23	Downgrade	BofA Securities	Buy → Underperform
Jul-12-23	Downgrade	JP Morgan	Overweight → Neutral
May-23-23	Initiated	CL King	Buy
May-15-23	Downgrade	Wolfe Research	Peer Perform → Underperform
Apr-03-23	Upgrade	Citigroup	Neutral → Buy
Mar-31-23	Initiated	B. Riley Securities	Buy
Mar-10-23	Upgrade	Citigroup	Sell → Neutral
Feb-07-23	Downgrade	Wolfe Research	Outperform → Peer Perform
Nov-22-22	Initiated	BofA Securities	Buy
Jul-11-22	Downgrade	Citigroup	Neutral → Sell
Apr-06-22	Initiated	Wolfe Research	Outperform
Nov-19-21	Upgrade	Citigroup	Sell → Neutral
Oct-01-21	Downgrade	Citigroup	Neutral → Sell
Oct-01-20	Downgrade	Citigroup	Buy → Neutral
Aug-21-20	Initiated	Piper Sandler	Neutral
Jul-09-20	Initiated	SVB Leerink	Outperform
May-27-20	Initiated	Citigroup	Buy
Aug-20-19	Initiated	Argus	Buy
Apr-29-19	Initiated	BMO Capital Markets	Outperform
Apr-29-19	Initiated	BofA/Merrill	Neutral
Apr-29-19	Initiated	JP Morgan	Overweight
Apr-29-19	Initiated	Stifel	Buy

View All

Silk Road Medical Inc Stock (SILK) Latest News

Silk Road Medical to Report First Quarter 2024 Financial Results on April 30, 2024

GlobeNewswire Inc.

Silk Road Medical's (SILK) New Launch to Aid Its TCAR Portfolio

Zacks Investment Research

Silk Road Medical Inc Stock (SILK) Financials Data

Silk Road Medical Inc (SILK) Revenue 2024

SILK reported a revenue (TTM) of $177.13 million for the quarter ending December 31, 2023, a +27.77% rise year-over-year.

Silk Road Medical Inc (SILK) Net Income 2024

SILK net income (TTM) was -$55.74 million for the quarter ending December 31, 2023, a -1.33% decrease year-over-year.

Silk Road Medical Inc (SILK) Cash Flow 2024

SILK recorded a free cash flow (TTM) of -$33.52 million for the quarter ending December 31, 2023, a +10.82% increase year-over-year.

Silk Road Medical Inc (SILK) Earnings per Share 2024

SILK earnings per share (TTM) was -$1.45 for the quarter ending December 31, 2023, a +6.45% growth year-over-year.

Silk Road Medical, Inc. operates as a medical device company in the United States. It offers ENROUTE Transcarotid Neuroprotection System that is used to directly access the common carotid artery and initiate temporary blood flow reversal; ENROUTE Transcarotid Stent System, a self-expanding, self-tapering stent with clinical data regarding lasting safety outcomes; ENHANCE Transcarotid Peripheral Access Kit for use in gaining initial access to the common carotid artery; and ENROUTE 0.014 Guidewire for navigating and crossing the target lesion for delivery of interventional devices. The company was founded in 2007 and is headquartered in Sunnyvale, California.